Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
19.12
-0.38 (-1.95%)
At close: Oct 10, 2025, 4:00 PM EDT
19.51
+0.39 (2.04%)
After-hours: Oct 10, 2025, 6:22 PM EDT
Seres Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Seres Therapeutics stock have a consensus rating of "Hold" and an average price target of $14.33, which forecasts a -25.05% decrease in the stock price over the next year. The lowest target is $6.00 and the highest is $22.
Price Target: $14.33 (-25.05%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Seres Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 → $22 | Strong Buy | Maintains | $14 → $22 | +15.06% | Sep 24, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades $1.25 → $6 | Strong Buy → Hold | Downgrades | $1.25 → $6 | -68.62% | May 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +30.75% | Mar 20, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $20 → $15 | Strong Sell | Maintains | $20 → $15 | -21.55% | Mar 14, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $200 | Strong Buy | Maintains | $200 | +946.03% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
0.31
from 0.02
Increased by 1,657.01%
EPS Next Year
-10.38
from 0.31
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.84 | -9.69 | |
| Avg | 0.31 | -10.38 | |
| Low | -1.12 | -11.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 10,398.2% | - | |
| Avg | 1,657.0% | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.